Stress – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:21:45 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Stress – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Orforglipron for stress urinary incontinence in women with obesity or overweight https://clinicaltrials.eu/trial/orforglipron-for-stress-urinary-incontinence-in-women-with-obesity-or-overweight/ Wed, 29 Apr 2026 15:07:57 +0000 https://clinicaltrials.eu/trial/orforglipron-for-stress-urinary-incontinence-in-women-with-obesity-or-overweight/ This clinical trial studies stress urinary incontinence, a condition where urine leaks during physical activities such as coughing, sneezing, laughing, or exercising. This type of incontinence occurs when the muscles that support the bladder and control urine release become weakened. The study focuses specifically on women who also have obesity or are overweight, as excess body weight can place additional pressure on the bladder and pelvic muscles, potentially worsening incontinence symptoms.

The trial investigates whether a medication called Orforglipron, taken as a tablet once daily by mouth, can help reduce the number of incontinence episodes experienced each week. Orforglipron belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking a natural hormone in the body that helps regulate appetite and body weight. By potentially helping participants lose weight, this medication may also reduce pressure on the bladder and improve incontinence symptoms. Some participants will receive placebo instead of the active medication.

The study aims to determine if Orforglipron is more effective than placebo in decreasing the frequency of urinary leakage episodes. Participants will take one tablet daily throughout the treatment period, and their incontinence episodes will be monitored and recorded. This is a Phase 3 trial sponsored by Eli Lilly, designed to evaluate both the effectiveness and safety of the medication in this specific patient population.

]]> A Study of Oxytocin Nasal Spray to Reduce Psychological Stress in Women Who Have Recovered from Breast Cancer https://clinicaltrials.eu/trial/a-study-of-oxytocin-nasal-spray-to-reduce-psychological-stress-in-women-who-have-recovered-from-breast-cancer/ Wed, 29 Apr 2026 15:06:58 +0000 https://clinicaltrials.eu/trial/a-study-of-oxytocin-nasal-spray-to-reduce-psychological-stress-in-women-who-have-recovered-from-breast-cancer/ This study focuses on individuals who have survived breast cancer and examines how oxytocin nasal spray might help reduce stress levels after cancer treatment. Oxytocin is a naturally occurring hormone in the body that may have stress-reducing properties. The study will evaluate whether this treatment can help improve emotional well-being in people who have completed their cancer therapy.

During the study, participants will receive either oxytocin nasal spray or a placebo nasal spray containing salt water. The treatment will be given through the nose for up to 5 days. Throughout the study period, participants will complete various questionnaires about their stress levels, emotional state, sleep quality, and thinking abilities. They will also perform some computer-based tasks to assess their cognitive function.

The study aims to understand if using oxytocin nasal spray can help reduce psychological distress that many people experience after breast cancer treatment. The research will measure changes in stress levels, anxiety, depression, and overall quality of life to determine if this treatment approach could be beneficial for breast cancer survivors.

]]>